PCRI is a 501(c) (3)
Not-for-profit public charity
To Learn More:
PCRI Mission
PCRI Staff & Boards
New to PCRI
Basics of PC
Undiagnosed
Newly Diagnosed
Local Therapies
Systemic Therapies
Androgen Independent
High Risk PC
Treatment Side-Effects
Software & Forms
Resources & Links
Donate Helpline Decision
Aide About
Us Español 
Newsletter PCRI
Papers Resources Search
General Prostate Cancer NewsPCRI is pleased to provide general prostate cancer news items courtesy of CancerConsultants.com Inc. whose mission is “to empower patients with current information on all aspects of the management of Prostate Cancer in order to provide support and hope, as well as to facilitate informed decisions”.
Latest Prostate Cancer NewsRadiofrequency Ablation Effective for Lung Tumors (7/16/2008)
The use of radiofrequency ablation for the treatment of lung cancer, or pulmonary metastases (cancer that has spread from site of origin to the lung) provides an effective and safe therapeutic option for some patients. These results were recently published in the Lancet Oncology.Denosumab Improves Bone Density in Prostate Cancer Patients (7/14/2008)
In a Phase III clinical trial among men receiving androgen-deprivation therapy for nonmetastatic prostate cancer, treatment with investigational drug denosumab improved bone density and reduced the risk of vertebral fractures.Immediate Hormone Therapy May Not Improve Outcomes in Elderly Men with Prostate Cancer (7/10/2008)
Treatment with immediate hormone therapy may not improve outcomes compared with conservative management among elderly men with prostate cancer. These results were recently published in the Journal of the American Medical Association.Finasteride May Prevent Prostate Cancer Without Increased Risk of Aggressive Cancers (6/26/2008)
Treatment with finasteride for seven years reduced the incidence of prostate cancer by approximately 25% without increasing the incidence of aggressive prostate cancers. These findings, which included a reanalysis of previously reported results, were published in Cancer Prevention Research.Bone Marker Associated with Survival in Breast, Prostate, and Lung Cancers (6/23/2008)
The bone marker N-telopeptide of type I collagen (NTX) is associated with skeletal-related events and survival among patients with cancer that has spread to the bone (bone metastases). Improved outcomes may be achieved by reducing these markers through treatment with agents such as Zometa® (zoledronic acid). These results were recently published in the journal Cancer.
Copyright ©2005 CancerConsultants.com. All Rights Reserved.
General Prostate Cancer News Archives
Prostate Cancer Research Institute (PCRI)
Material provided by PCRI is intended for educational purposes for discussion with your physician and should not be considered as medical advice. Information and opinions expressed on this website are not an endorsement by PCRI for any treatment, product or service.